



Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-12 (canceled).

Claim 13 (original): A purified monoclonal antibody which specifically recognizes a peptide having the amino acid sequence of SEQ ID NO:2.

Claim 14 (canceled).

Claim 15 (currently amended): A therapeutic composition for increasing antimalignin antibody concentration in a patient in need thereof comprising a peptide selected from the group consisting of [a] the peptide of SEQ ID NO:1, [a] the peptide of SEQ ID NO:2, ~~aglycoprotein 10B~~, and combinations thereof.

Claim 16-23 (canceled).

Claim 24 (currently amended): A kit for determining the concentration of aglycoprotein 10B antigenic epitopes present in blood of a patient comprising at least one blood collection tube or pipette and ~~antimalignin antibody~~ an antibody that specifically recognizes SEQ ID NO:1 or SEQ ID NO:2 wherein said antibody is coated on the inner surface of said collection tube or pipette.

Claim 25 (currently amended): A kit for determining the concentration of anti-malignin antibody present in blood of a patient comprising at least one blood collection tube or pipette and a peptide having the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

Claim 26 (previously presented): The kit of claim 25 wherein the peptide is coated on the inner surface of the tube or pipette.

Claim 27 (original): An isolated nucleic acid encoding a peptide comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

Claims 28-31 (canceled).